Spironolactone Tablet
Product Images NDC 70518-4350

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 70518-4350). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Spironolactone 25 mg oral tablets packaging label showing 100 tablets per box. The label includes the NDC number 70518-4350-00, repackaged by RemedyRepack Inc. in Indiana, PA. Storage instructions, manufacturer information (Bryant Ranch Prepack, Burbank, CA), and a reminder that the product is RX only are also visible.*

FDA Label Image

Mm2 (Spironolactone 25mg 70518 4350 01)

Label for Spironolactone 25 mg oral tablet, packaged as a single tablet. The label shows product name, strength, quantity, and description as round white tablet. It includes repackager RemedyRepack Inc., Indiana, PA, contact number, and manufacturer Bryant Ranch Prepack, Burbank, CA. Storage instructions and safety warnings are also present.*

FDA Label Image

Structure (Spironolactone 01)

Chemical structure of spironolactone showing its steroid backbone with attached functional groups, including a lactone ring and a thioacetate moiety.*

FDA Label Image

Figure 1 (Spironolactone 02)

A line chart comparing the probability of two groups over time in months, labeled 'Spironolactone' and 'Placebo'. The vertical axis is probability from 0 to 1, the horizontal axis shows duration up to 48 months, with Spirnolactone represented by a solid line and Placebo by a dashed line, including sample sizes for both groups.*

FDA Label Image

Figure 2 (Spironolactone 03)

A forest plot depicting hazard ratios (HR) and 95% confidence intervals (CI) comparing spironolactone to placebo across various subgroups including age, sex, race, left ventricular ejection fraction (LVEF), heart failure types, NYHA class, diabetes status, serum creatinine, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use. The plot shows HR values and confidence intervals visually represented by squares and horizontal lines respectively, relative to a line of no effect.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.